



# HIV Treatment-As-Prevention Research: Authors' Reply

## Citation

Bärnighausen, Till, Nir Eyal, and Dan Wikler. 2015. "HIV Treatment-As-Prevention Research: Authors' Reply." *PLoS Medicine* 12 (3): e1001799. doi:10.1371/journal.pmed.1001799. <http://dx.doi.org/10.1371/journal.pmed.1001799>.

## Published Version

doi:10.1371/journal.pmed.1001799

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351090>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

FORMAL COMMENT

# HIV Treatment-As-Prevention Research: Authors' Reply

Till Bärnighausen<sup>1,2\*</sup>, Nir Eyal<sup>3</sup>, Dan Wikler<sup>1</sup>

**1** Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America, **2** Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa, **3** Department of Global Health and Society, Harvard Medical School, Boston, Massachusetts, United States of America

\* [tbaernig@hsph.harvard.edu](mailto:tbaernig@hsph.harvard.edu)



OPEN ACCESS

**Citation:** Bärnighausen T, Eyal N, Wikler D (2015) HIV Treatment-As-Prevention Research: Authors' Reply. *PLoS Med* 12(3): e1001799. doi:10.1371/journal.pmed.1001799

**Received:** January 8, 2015

**Accepted:** January 30, 2015

**Published:** March 10, 2015

**Copyright:** © 2015 Bärnighausen et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** TB was supported by grant 1R01-HD058482-01 from the National Institute of Child Health and Human Development, the Wellcome Trust and the Agence National de Recherches sur le Sida et les Hépatites Viral. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** TB is a named contributor to the 2013 WHO ART guidelines as well as an investigator on the ANRS 12249 Treatment-as-Prevention trial in South Africa and the MaxART study in Swaziland. NE and DW declare that they have no competing interests.

**Abbreviations:** ART, antiretroviral treatment; PMTCT, prevention of mother-to-child transmission; TasP, treatment-as-prevention.

We thank Richard Hayes and colleagues for their commentary [1] on our *PLOS Medicine* article [2]. We share the desire to learn through rigorous research whether HIV treatment-as-prevention (TasP) works in population-wide implementation. Our article pointed out that the 2013 WHO antiretroviral treatment (ART) guidelines put the on-going TasP trials at risk of failing “in their primary aim to establish the effectiveness of TasP in general populations in sub-Saharan Africa because of insufficient power” [2]. The 2013 WHO guidelines recommend substantially expanded ART eligibility. The host countries of the TasP trials are adopting the guidelines as national policy, and currently accepted ethical standards for clinical trials oblige the TasP trials to do likewise for patients enrolled in all trial arms. The problem is that the trials were designed and originally powered under the more restricted, previous ART eligibility standards and may thus become insufficiently powered to test the TasP hypothesis [2].

Hayes and colleagues assert that the HPTN071 (PopART) trial does not face this risk because “[t]he study power for the Arm A versus C comparison, the main study comparison, remains very high” when all PopART arms offer ART under the expanded eligibility standards [1]. But this comparison of Arms A versus C does not test the TasP hypothesis. Rather, it tests the very different hypothesis that an extensive HIV combination prevention package can reduce HIV incidence.

To explain, TasP aims to achieve substantial HIV incidence reductions through immediate ART initiation in all HIV-infected individuals [3–5]. In contrast, HIV combination prevention packages aim to achieve the same goal through implementation of many different interventions believed to be effective in preventing HIV [6–8]. PopART is to test both strategies. Our concern regards only the former; i.e., its test of TasP.

The PopART protocol published in *Trials* [9] in 2014 makes clear why PopART faces the risk of failing to test the TasP hypothesis because of insufficient power, just like the other trials. PopART was designed and powered “to detect a difference in incidence between Arms A and C (reflecting the full impact of the intervention), as well as the difference in intervention effect between Arms A and B (reflecting the additional effect of immediate HIV treatment compared with current national guidelines)” [9].

The additional effect of immediate HIV treatment (Arm A versus B) is the effect of TasP, namely, offering immediate HIV treatment when the “uptake and coverage of [other] HIV services is substantially expanded” [1]. Regarding this test, Hayes and colleagues write that “[f]ollowing adoption of 2013 guidelines, there will be a smaller number of HIV-infected individuals offered treatment in Arm A who would not be eligible for treatment if in Arm B communities, reducing the power to demonstrate a difference between Arms A and B” [1]. It is precisely

this comparison that tests the TasP hypothesis in PopART and that is now threatened to fail because of insufficient power (Table 1). If WHO follows the United States [10,11] in recommending immediate ART initiation for all HIV-infected people in the 2015 WHO ART guidelines, PopART will face the even larger threat of completely losing the Arm A versus B comparison [12].

In contrast to the Arm A versus B comparison, the difference between Arms A and C in PopART is the effect of an extensive HIV combination prevention package (“the full intervention” [9]), which includes immediate HIV treatment but also many other interventions: male circumcision, condom promotion, home-based behavioural HIV risk-reduction counselling, home-based HIV testing and referral to HIV treatment and care, home-based screening for sexually transmitted infections and referral for treatment, home-based screening for tuberculosis and referral for treatment, home-based identification of pregnant women and encouragement to attend antenatal care, and encouragement to access prevention of mother-to-child transmission services for pregnant women who test HIV-positive [9].

If the PopART combination prevention package is shown to be effective, any subset of interventions in the package—which may or may not include TasP—could be responsible for the effect, and we cannot know which. Importantly, based on this comparison it is impossible to rule out that any significant effect is due entirely to those interventions in the package that have already been firmly established to be effective in preventing HIV, such as male circumcision [13–15]. The comparison of PopART Arm A versus C is thus not a valid test of the TasP hypothesis (Table 1).

Given our shared interest in testing TasP, we are glad to read that Hayes and colleagues broadly endorse two of our proposals: to increase the power to test the TasP hypothesis by pooling data across trials and to consider randomised stepped-wedge scale-up of TasP as an additional strategy to establish TasP effectiveness.

**Table 1. The two interventions the HPTN071 (PopART) trial aims to test.**

Intervention tested by PopART	Test	Interpretation of a significant difference between the two PopART arms	Effect of countries adopting the 2013 WHO ART guidelines	Effect of countries adopting policies of immediate ART initiation in all HIV-infected individuals
<b>An extensive HIV combination prevention package</b>	PopART Arm A versus C	Some subset of the interventions in the HIV combination prevention package—which may or may not include TasP—is effective in reducing HIV incidence	“The study power for the Arm A versus C comparison, the main study comparison, remains very high.” [1]	The study power for the Arm A versus C comparison would likely remain high
<b>HIV treatment-as-prevention (TasP)</b>	PopART Arm A versus B	TasP is effective in reducing HIV incidence	“...there will be a smaller number of HIV-infected individuals offered treatment in Arm A who would not be eligible for treatment if in Arm B communities, reducing the power to demonstrate a difference between Arms A and B.” [1]	Arm B would become equivalent to Arm A. From this point onward, none of the information collected in PopART would contribute to testing TasP

doi:10.1371/journal.pmed.1001799.t001

## Author Contributions

Wrote the paper: TB NE DW. Agree with manuscript results and conclusions: TB NE DW. All authors have read, and agree that they meet, ICMJE criteria for authorship.

## References

1. Hayes R, Fidler S, Cori A, Fraser C, Floyd S, et al. (2015) HIV treatment-as-prevention research: taking the right road at the crossroads. *PLoS Med* 12(3): e1001800. doi: [10.1371/journal.pmed.1001800](https://doi.org/10.1371/journal.pmed.1001800)
2. Bärnighausen T, Eyal N, Wikler D (2014) HIV treatment-as-prevention research at a crossroads. *PLoS Med* 11: e1001654. doi: [10.1371/journal.pmed.1001654](https://doi.org/10.1371/journal.pmed.1001654) PMID: [24892694](https://pubmed.ncbi.nlm.nih.gov/24892694/)
3. The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group (2012) HIV treatment as prevention: models, data, and questions—towards evidence-based decision-making. *PLoS Med* 9: e1001259. doi: [10.1371/journal.pmed.1001259](https://doi.org/10.1371/journal.pmed.1001259) PMID: [22802739](https://pubmed.ncbi.nlm.nih.gov/22802739/)
4. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. *Lancet* 373: 48–57. doi: [10.1016/S0140-6736\(08\)61697-9](https://doi.org/10.1016/S0140-6736(08)61697-9) PMID: [19038438](https://pubmed.ncbi.nlm.nih.gov/19038438/)
5. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendauid E, et al. (2012) HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. *PLoS Med* 9: e1001245. doi: [10.1371/journal.pmed.1001245](https://doi.org/10.1371/journal.pmed.1001245) PMID: [22802730](https://pubmed.ncbi.nlm.nih.gov/22802730/)
6. Vermund SH, Fidler SJ, Ayles H, Beyers N, Hayes RJ (2013) Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. *J Acquir Immune Defic Syndr* 63 Suppl 2: S221–227. doi: [10.1097/QAI.0b013e318299c3f4](https://doi.org/10.1097/QAI.0b013e318299c3f4) PMID: [23764639](https://pubmed.ncbi.nlm.nih.gov/23764639/)
7. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN (2011) Combination HIV prevention: significance, challenges, and opportunities. *Curr HIV/AIDS Rep* 8: 62–72. doi: [10.1007/s11904-010-0063-3](https://doi.org/10.1007/s11904-010-0063-3) PMID: [20941553](https://pubmed.ncbi.nlm.nih.gov/20941553/)
8. Merson M, Padian N, Coates TJ, Gupta GR, Bertozzi SM, et al. (2008) Combination HIV prevention. *Lancet* 372: 1805–1806. doi: [10.1016/S0140-6736\(08\)61752-3](https://doi.org/10.1016/S0140-6736(08)61752-3) PMID: [19027478](https://pubmed.ncbi.nlm.nih.gov/19027478/)
9. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, et al. (2014) HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment—a study protocol for a cluster randomised trial. *Trials* 15: 57. doi: [10.1186/1745-6215-15-57](https://doi.org/10.1186/1745-6215-15-57) PMID: [24524229](https://pubmed.ncbi.nlm.nih.gov/24524229/)
10. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents (2013) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. <http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>
11. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. *JAMA* 308: 387–402. doi: [10.1001/jama.2012.7961](https://doi.org/10.1001/jama.2012.7961) PMID: [22820792](https://pubmed.ncbi.nlm.nih.gov/22820792/)
12. WHO (2014) Systematic reviews to support the antiretroviral therapy (ART) consolidated guidelines Geneva: WHO.
13. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. *Lancet* 369: 643–656. PMID: [17321310](https://pubmed.ncbi.nlm.nih.gov/17321310/)
14. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. *Lancet* 369: 657–666. PMID: [17321311](https://pubmed.ncbi.nlm.nih.gov/17321311/)
15. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. *PLoS Med* 2: e298. PMID: [16231970](https://pubmed.ncbi.nlm.nih.gov/16231970/)